Form 4: Revance Therapeutics CEO Acquires Shares Through Employee Stock Purchase Plan

Revance Therapeutics CEO Mark Foley acquired 1,000 shares of common stock through the company's Employee Stock Purchase Plan on December 31, 2024.

Summary

• On December 31, 2024, Mark J. Foley, CEO of Revance Therapeutics, acquired 1,000 shares of common stock through the company's 2014 Employee Stock Purchase Plan at a price of $2.1845 per share.
• Following the transaction, Mr. Foley directly owns 996,935 shares of Revance Therapeutics common stock.
• Additionally, 110,913 shares are held indirectly through the Foley Family Trust.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard transaction. The CEO's participation in the employee stock purchase plan is a mildly positive signal, but not significantly impactful.

Positives

• The CEO's participation in the Employee Stock Purchase Plan could be seen as a positive signal, indicating confidence in the company's future.

Industry Context

This filing is a routine disclosure related to insider transactions and doesn't necessarily reflect a major shift in the company's outlook or strategy. It's common for executives to participate in employee stock purchase plans.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.

Key Dates

Keywords

Revance Therapeutics, Mark Foley, Employee Stock Purchase Plan, RVNC, Beneficial Ownership, Form 4, SEC Filing